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Introduction {#sec001}
============

Mitochondria produce the majority of ATP required by the body by oxidative phosphorylation (OXPHOS). Mitochondrial DNA (mtDNA), the unique mitochondrial genome, encodes 13 polypeptides---the subunits of respiratory complexes, and rRNA and tRNA molecules needed for translation of these polypeptides. Mutations in mtDNA result in reduced ATP production because they lead to abnormal structure of respiratory chain subunits or reduced translation of mitochondrial proteins, and underlie various disorders, termed mitochondrial diseases \[[@pone.0213283.ref001]\].

Until now, many mutations in mtDNA have been reported as candidate causative mutations of mitochondrial diseases \[[@pone.0213283.ref002]\]. All pathogenic mtDNA mutations result in reduced ATP production as a primary phenotype. However, the resultant disease phenotypes are diverse, and the mechanisms of expression of disease phenotypes are not well known. The most effective approach to elucidate these mechanisms is generation and analysis of animal models of disease, in which an animal harbors a mutation that corresponds to a disease of interest. However, because techniques for artificial manipulation and mutagenesis of mtDNA are not well established, generating animal models of disease corresponding to each human mitochondrial disease phenotype is very difficult.

Instead of using artificial mutagenesis, we have previously concentrated native mutations that exist in mouse cell lines at a very low frequency, and we then generated some mouse models of mitochondrial diseases \[[@pone.0213283.ref003]--[@pone.0213283.ref006]\]. However, this approach limits the array of mtDNA mutations as a source of mouse models of disease.

To overcome this difficulty, we focused on the mtDNA of "mutator mice". Mutator mice have been generated by disrupting the proofread function of DNA polymerase γ (PolG), the only DNA polymerase for mtDNA \[[@pone.0213283.ref007], [@pone.0213283.ref008]\]. These mice accumulate random mtDNA mutations attributed to replication errors with age. Such diverse random mtDNA mutations possibly comprise mutations corresponding to certain human pathogenic mutations or novel pathogenic mutations. Hence, mtDNA of mutator mice is an attractive starting material for exploring pathogenic mtDNA mutations. However, the research group that created the mutator mice reported a strong elimination of non-synonymous changes in protein-coding genes and loss of variation of mutations in subsequent generations after crossing a mutator female with a wild-type male \[[@pone.0213283.ref009]\]. If the selective pressure that eliminates harmful mutations is operational in these mice, it would be difficult to concentrate certain pathogenic mtDNA mutations in mouse by repeated crossing.

To address this challenge, we conceived an idea of using a cultured cell line as a research tool. For example, although A3243G, the most frequent pathogenic mutation in mtDNA in human, is observed only as a heteroplasmy (mixture of mutant and normal mtDNA) in patients \[[@pone.0213283.ref010]\], it can exist as a homoplasmy (pure mutant mtDNA) in a cultured cell line \[[@pone.0213283.ref011]\]. This behavior is also common for other pathogenic mtDNA mutations. Furthermore, while mouse or human lacking mtDNA cannot exist, mtDNA-less cells (ρ^0^ cells) can be established and maintained in nutrient-rich medium supplemented with pyruvate and uridine \[[@pone.0213283.ref012], [@pone.0213283.ref013]\]. These observations suggest that cultured cell lines are resistant to severe respiration defects, and show higher tolerance to harmful pathogenic mtDNA than cells in tissue. If that indeed is the case, it should be possible to concentrate pathogenic mtDNA mutations using a cell line harboring mtDNA derived from mutator mouse.

In the current study, we established a transmitochondrial cytoplasmic hybrid (cybrid) cell line that harbors mtDNA containing random mutations by introducing platelet mtDNA from mutator mouse into mouse ρ^0^ cells. By evaluating respiratory function and the mtDNA sequence, we investigated whether mtDNA molecules containing random mutations might serve as a starting material for the generation of novel mouse models of disease. Further, we evaluated the difference in mtDNA mutation tolerance between mouse tissue and a cultured cell line, and the potential mechanisms that link respiration defects and random mtDNA mutations.

Materials and methods {#sec002}
=====================

Cells and cell culture {#sec003}
----------------------

B82 is a fibrosarcoma cell line (ECACC 08062522) derived from the L929 fibroblast line established from C3H/An mouse. B82, ρ^0^B82 \[[@pone.0213283.ref013]\], and cybrids were grown at 37°C with 5% CO~2~ in RPMI 1640 medium (Nissui, Tokyo, Japan) containing 10% FBS (Sigma-Aldrich, St. Louis, MO), uridine (50 mg/mL), and pyruvate (0.1 mg/mL). All experiments were performed in accordance with the institutional guidelines.

Mice {#sec004}
----

The control C57BL/6J mouse was purchased from a breeder (CLEA Japan, Tokyo, Japan). The mutator mouse line with C57BL/6J nuclear background was generated in our previous study \[[@pone.0213283.ref014]\]. All animal care and use were approved by the Institutional Animal Care and Use Committee of the University of Tsukuba.

Generation of transmitochondrial cybrids {#sec005}
----------------------------------------

As mtDNA donors, 10-week-old male C57BL/6J mouse and 10-month-old male *PolG*^mut/mut^ mutator mouse were used. Blood samples (approximately 1 mL) were taken from each mouse under anesthesia and then centrifuged at 300 × *g* for 5 min. The collected platelet-rich supernatant was combined with 1 × 10^4^ ρ^0^B82 cells, and fused using the polyethylene glycol (PEG 1,500, Roche, Basel, Switzerland) method. Unfused nuclear donor ρ^0^B82 cells were eliminated by incubation in a selection medium lacking uridine and pyruvate. B82mtΔ cells have been generated previously \[[@pone.0213283.ref003]\]. Detailed procedures for the generation of transmitochondrial cybrids are described elsewhere \[[@pone.0213283.ref015]\]. The replacement of mtDNA in cybrids was confirmed by PCR-restriction fragment length polymorphism. Briefly, to distinguish the polymorphism at position 9,348 (G in C57BL/6J mouse and A in C3H/An mouse), mtDNA was purified using an mtDNA extractor CT kit (Wako, Osaka, Japan), and the 9,320--9,479-bp region was amplified by PCR. Forward primer *5′-AGC ATG ATA CTG ACA TTT TGT AGA CcT-3′* (lowercase letter indicates the mismatch site) and reverse primer *5′-GAT AAC AGT GTA CAG GTT AAT TAC TCT CTT CTG-3′* were used. Combination of the PCR-generated mismatch with the specific polymorphism created a restriction site for *Xsp* I in C57BL/6J mtDNA, such that *Xsp* I digestion generated 134-bp and 26-bp fragments, and an intact 160-bp amplicon in C3H/An mtDNA. Cybrid cells were cultured for at least 2 months after fusion before mtDNA sequence analysis.

Biochemical determination of respiratory enzyme activity {#sec006}
--------------------------------------------------------

Mitochondrial fraction was prepared from homogenized cell lysates, and mitochondrial respiratory complex activities were determined. To determine the activities of complexes I + III, II + III, and IV, NADH and oxidized cytochrome *c*, sodium succinate and oxidized cytochrome *c*, and reduced cytochrome *c* were added as substrates, respectively. Reduction (I + III, II + III) and oxidation (IV) of cytochrome *c* were detected as a change in sample absorbance at 550 nm. Mean reaction rates for B82mtB6 and B82mt*PolG*^mut/mut^ cells were calculated, and are reported as relative values, with B82mtB6 values considered to be 100%.

Cytochrome *c* oxidase (COX)/succinate dehydrogenase (SDH) staining {#sec007}
-------------------------------------------------------------------

Cytochemical analysis of COX and SDH activity was performed as described previously \[[@pone.0213283.ref016]\], using coverslips with growing cells.

Deep-sequence analysis of mtDNA {#sec008}
-------------------------------

mtDNA was extracted from cybrid cells by using an mtDNA extractor CT kit (Wako), electrophoresed on agarose gel, and purified by using the FastGene Gel/PCR Extraction Kit (Nippon Genetics, Tokyo, Japan). To compare the mtDNA populations between cybrids and parental platelets, platelets were prepared from the littermate of each mtDNA-donor mouse as described above at the same timing of the generation of cybrids, and mtDNA was extracted by using a Gentra Puregene Tissue Kit (QIAGEN, Venlo, Netherlands). Purified mtDNA was fragmented into approximately 100-bp fragments, and sequenced using HiSeq 2500 (Illumina, San Diego, CA), with chrM of the UCSC mm10 (<http://hgdownload.cse.ucsc.edu/goldenPath/mm10/bigZips/chromFa.tar.gz>) as a reference sequence. Mutations occurring at a frequency over 1% were analyzed to determine their effect on the encoded amino acid, and to check whether the mutation sites were homologous to sites of human pathogenic mtDNA mutation. Alignments of nucleic acid and amino acid sequences from mouse and human were performed for every gene and region using T-COFFEE (<http://tcoffee.vital-it.ch/apps/tcoffee/do:regular>).

Native polyacrylamide gel electrophoreses (PAGE) {#sec009}
------------------------------------------------

The crude mitochondrial fraction was isolated from cybrid homogenates by centrifugation (900 × *g* for 5 min). The supernatant was collected and re-centrifuged at 5,000 × *g* for 10 min. Isolated mitochondria (1 mg/mL) were solubilized at 4°C for 30 min with 1% digitonin in buffer (20 mM bis-Tris, 0.1 M NaCl, and 10% glycerol, pH 7.0), and centrifuged at 100,000 × *g* for 15 min. The resulting supernatants were subjected to electrophoresis. Electrophoresis was conducted as described before\[[@pone.0213283.ref017]\] using NativePAGE 3--12% Bis-Tris Protein Gels (Thermo Fisher Scientific, Waltham, MA). To detect respiratory complexes, proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Thermo Fisher Scientific). The membrane was blocked with 5% skim milk in TBS-T, and MitoProfile Total OXPHOS Blue Native WB Antibody Cocktail (at 1:250, MS603, Mitosciences, Eugene, OR) was used as the primary antibody, following the manufacturer's recommendations. Horseradish peroxidase-linked anti-mouse IgG (at 1:3000, \#7076, Cell Signaling Technology, Danvers, MA) was used as the secondary antibody, and incubated with ECL substrate (Thermo Fisher Scientific) in agreement with the manufacturer's guidelines. Detection was performed using the ImageQuant LAS4000 (GE Healthcare, Little Chalfont, UK). To evaluate in-gel complex I activity, gels were incubated in assay buffer (2 mM Tris-HCl, 0.1 mg/mL NADH, and 2.5 mg/mL nitro blue tetrazolium chloride (NTB), pH 7.4).

Quantification of proteins {#sec010}
--------------------------

Total protein was extracted from cybrids using the EzRIPA Lysis Kit (ATTO, Tokyo, Japan). SDS-PAGE was performed using NuPAGE 4--12% Bis-Tris gels (Thermo Fisher Scientific) and MOPS Running Buffer (Thermo Fisher Scientific). Then, the proteins were transferred to PVDF membrane. After blocking with a PVDF Blocking Reagent (TOYOBO, Osaka, Japan), membranes were incubated with the following primary antibodies: anti-NDUFA9 (ab14713, Abcam, Cambridge, UK), anti-MT-ND1 (ab181848, Abcam), anti-SDHA (\#11998, Cell Signaling Technology), anti-COX IV (\#4850, Cell Signaling Technology), anti-MT-COI (ab14705, Abcam), anti-Hsp60 (\#12165, Cell Signaling Technology), anti-mtHsp70 (\#3593, Cell Signaling Technology), anti-Tid1 (\#4775, Cell Signaling Technology), anti-Lonp1 (NBP1-81734, Novus Biologicals, Littleton, CO), and anti-α--Tubulin (T-5168, Sigma-Aldrich). All primary antibodies described above were used at 1:1000 dilution. As the secondary antibodies, horse radish peroxidase-linked anti-mouse IgG (at 1:3000, \#7076, Cell Signaling Technology) or anti-rabbit IgG (at 1:3000, \#7074, Cell Signaling Technology) was used. The membranes were then incubated with ECL substrate (Thermo Fisher Scientific). Signal detection and quantification were performed using the ImageQuant LAS4000 (GE Healthcare) and MultiGauge software (FUJIFILM, Tokyo, Japan).

Statistical analysis {#sec011}
--------------------

The sample size of each test and statistical method used for data analysis are stated in each figure legend. Statistical analyses were conducted using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA). *P*-value of less than 0.05 was considered to indicate statistically significant differences between samples.

Results {#sec012}
=======

Establishment of transmitochondrial cybrid cells harboring random mtDNA mutations {#sec013}
---------------------------------------------------------------------------------

Previously, based on the original papers by Trifunovic *et al*. \[[@pone.0213283.ref007]\] and Kujoth *et al*. \[[@pone.0213283.ref008]\], we have introduced the D257A mutation into the *PolG* gene of C57BL/6J mouse and generated mtDNA mutator mouse \[[@pone.0213283.ref014]\]. As the mtDNA donor, we used a 10-month-old male *PolG*^mut/mut^ mouse, a generation 8 offspring of *PolG*^+/mut^-to-*PolG*^+/mut^ mating. Because successive generations of mice inherit maternal mtDNA mutations by germline transmission, it is thought that they harbor more mtDNA mutations than generation 1 offspring \[[@pone.0213283.ref018]\]. A 10-week-old C57BL/6J male mouse was used as a control. Platelets obtained from each mouse were fused with ρ^0^B82 cells \[[@pone.0213283.ref013]\], which are mtDNA-less cells from the B82 fibrosarcoma cell line derived from C3H/An mouse. Thus, B82mtB6 and B82mt*PolG*^mut/mut^ cybrids were established, accordingly ([S1 Fig](#pone.0213283.s001){ref-type="supplementary-material"}). Analysis of strain-specific mtDNA polymorphisms confirmed the replacement of C3H/An-type mtDNA by C57BL/6J-type mtDNA ([Fig 1A](#pone.0213283.g001){ref-type="fig"}). Measurements of respiratory complex activity revealed remarkable respiration defects in B82mt*PolG*^mut/mut^ cells ([Fig 1B](#pone.0213283.g001){ref-type="fig"}). Further, specific staining confirmed severe COX (complex IV) deficiency in B82mt*PolG*^mut/mut^ cells ([Fig 1C](#pone.0213283.g001){ref-type="fig"}). On the other hand, the staining indicated that the SDH (complex II) activity in B82mt*PolG*^mut/mut^ cells was rather up-regulated ([Fig 1C](#pone.0213283.g001){ref-type="fig"}). Thus, the reduced complex II + III activity shown in [Fig 1B](#pone.0213283.g001){ref-type="fig"} appeared to stem from a defect in complex III, and not a defect in complex II.

![Establishment of transmitochondrial cybrid cells and their characterization.\
(**A**) Genotyping of mtDNA by PCR-restriction fragment length polymorphism confirmed the replacement of mtDNA in the constructed cybrids. Compared with the C57BL/6J mouse, mtDNA of the C3H/An mouse (the source of B82 cells) harbors G9348A polymorphism. Hence, the origin of mtDNA in the current study could be distinguished by detecting this strain-specific polymorphism (see [methods](#sec002){ref-type="sec"} for details). (**B**) Relative respiratory complex activities. Data are presented as the mean + S.D. \*\*\*\**P* \< 0.0001, according to the independent two-tailed *t*-test (*n* = 3). (**C**) COX/SDH staining of cybrid cells. Cells with normal COX activity stain brown, whereas cells with defective respiration stain blue. The images are representative of 3 replicates. Scale bar = 50 μm.](pone.0213283.g001){#pone.0213283.g001}

These observations indicated that the activities of respiratory complexes, except for complex II, in cells harboring mtDNA derived from the mutator mouse were severely impaired, and OXPHOS function was almost completely abolished in B82mt*PolG*^mut/mut^ cells.

B82mt*PolG*^mut/mut^ cells harbor various mtDNA mutations at high frequency {#sec014}
---------------------------------------------------------------------------

We then extracted mtDNA molecules from each cybrid and platelets obtained from the littermate of each mtDNA-donor mouse of the cybrids, and analyzed by deep-sequencing. More than 2 million reads were analyzed. The average depth of coverage of the entire mtDNA sequence was over 12,000× ([Table 1](#pone.0213283.t001){ref-type="table"}). Mutation analysis data are shown in S1 (cybrids) and S2 (platelets) Tables. The mutation frequency per 10 kb is shown in [Table 1](#pone.0213283.t001){ref-type="table"} and [Fig 2A](#pone.0213283.g002){ref-type="fig"}. As indicated in [Table 1](#pone.0213283.t001){ref-type="table"}, [Fig 2A and 2B](#pone.0213283.g002){ref-type="fig"}, mtDNA molecules from B82mt*PolG*^mut/mut^ cells harbored approximately eight times more mutations than those of B82mtB6 control cells. The mutation frequency was also higher than that of platelets obtained from a littermate of an mtDNA-donor ([Fig 2A and 2B](#pone.0213283.g002){ref-type="fig"}). Mutations occurring at a frequency of at least 1% in cybrids and platelets are shown in [Fig 2C and 2D](#pone.0213283.g002){ref-type="fig"}, respectively. Only seven mutations fulfilling this criterion were identified in B82mtB6 cells, in comparison with 137 mutations in B82mt*PolG*^mut/mut^ cells. Regarding platelets, 11 and 48 mutations were found at more than 1% of frequency in B6 and *PolG*^mut/mut^ mice, respectively. This indicated that B82mt*PolG*^mut/mut^ cells harbored more mutations that occurred at high frequency than the control cells and platelets of mutator mice. Moreover, majority of the mutation rates of these 137 mutations were either approximately 5%, 10%, or 40% ([Fig 2C](#pone.0213283.g002){ref-type="fig"}). Notably, however, comparison of the diversity of mutations revealed that platelets from *PolG*^mut/mut^ mice harbored more diverse mutations than their cybrids, B82mt*PolG*^mut/mut^ cells ([Fig 2E](#pone.0213283.g002){ref-type="fig"}).

![Deep-sequence analysis of the established cybrid cells.\
(**A**) Mutation frequency (per 10 kb) in each cybrid and platelet. The actual values are provided in [Table 1](#pone.0213283.t001){ref-type="table"}. (**B**) Mutation frequency of each base in the entire mtDNA. Data are presented as the mean + S.E. \*\*\*\**P* \< 0.0001 by 1-way ANOVA. (*n* = 16,299). The actual values are provided in [Table 1](#pone.0213283.t001){ref-type="table"}. Among all the detected mutations, only mutations occurring at a frequency of at least 1% in cybrid cells (**C**) and platelets (**D**) are shown. Green, yellow, and red bands indicate mutation ranges of 4--6%, 8--12%, and 30--50%, respectively. Blue band in (**C**) shows the *tRNA*^*Leu(UUR)*^ gene region. Rep. Ori., replication origin. (**E**) Comparison of diversity of mtDNA mutations. All types of substitution and insertion/deletion mutations were quantified independently, and total sums are shown (*e*.*g*., in the case of a base A mutated as A \> G, A \> T, and AinsAA, mutations for this base would be counted as 3). Note that platelets of *PolG*^mut/mut^ mice harbored more diverse mutations than B82mt*PolG*^mut/mut^ cells, despite a lower mutation frequency than that of B82mt*PolG*^mut/mut^ cells. (**F**) Mutation rates for each base in the *tRNA*^*Leu(UUR)*^ gene in cybrid cells. Data are presented as the mean + S.D. *P*-value calculated by using paired two-tailed *t*-test is indicated (*n* = 75).](pone.0213283.g002){#pone.0213283.g002}
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###### Overview of sequence analysis.

![](pone.0213283.t001){#pone.0213283.t001g}

  　                                                     　            B82mt         Platelets                   
  ------------------------------------------------------ ------------- ------------- ------------- ------------- --------
  On-target read number                                  2,038,897     2,902,204     5,173,781     7,516,437     
  Depth average                                          12,442        17,701        31,565        45,824        
  Coverage rate                                          \>3×          100.00        100.00        100.00        100.00
                                                         \>10×         100.00        100.00        100.00        100.00
                                                         \>20×         100.00        100.00        100.00        100.00
                                                         \>40×         99.99         100.00        100.00        100.00
  Total analyzed bases                                   192,221,549   273,833,727   498,203,226   728,866,493   
  Total mutations[\*](#t001fn001){ref-type="table-fn"}   59,960        686,532       81,320        1,018,148     
  Mutation frequency (bases/10 kb)                       3.12          25.07         1.63          13.97         
  Mutation frequency for each base (%)                   0.0307        0.2411        0.0165        0.1416        

\* The number of base substitutions and insertions/deletions.

Among mutations occurring at a frequency of \>1% in cybrid cells, mutations mapped to protein-coding regions are listed in [Table 2](#pone.0213283.t002){ref-type="table"}. Overall, 101 mutations were located in protein-coding regions; of these, 68 were non-synonymous mutations (67.3%). Mutations in the tRNA- or rRNA-coding, or non-coding regions are listed in [Table 3](#pone.0213283.t003){ref-type="table"}. Among mutations listed in Tables [2](#pone.0213283.t002){ref-type="table"} and [3](#pone.0213283.t003){ref-type="table"}, we attempted to identify mutations homologous to human pathogenic mtDNA mutations. Details of mutations occurring at homologous bases or affecting amino acids homologous to those of human pathogenic mutations listed in MITOMAP ([https://mitomap.org](https://mitomap.org/)), a human mitochondrial genome database, are shown in [S3 Table](#pone.0213283.s005){ref-type="supplementary-material"}.

10.1371/journal.pone.0213283.t002

###### Mutations in protein-coding regions occurring at a frequency above 1% in cybrid cells.

![](pone.0213283.t002){#pone.0213283.t002g}

  Gene            N.P.     Ref.[\*](#t002fn001){ref-type="table-fn"}   Mutation frequency   Most frequent change   Amino acid   Non-syn?[\*\*](#t002fn002){ref-type="table-fn"}   Human N.P.                     
  --------------- -------- ------------------------------------------- -------------------- ---------------------- ------------ ------------------------------------------------- --------------------- -------- --------
  *Nd1*           2,934    C                                           0.044                44.522                 \>T          62                                                R \> C                Yes      3,490
  3,010           T        0.014                                       41.861               \>C                    87           V \> A                                            Yes                   3,566    
  3,181           T        0.015                                       4.904                \>C                    144          V \> A                                            Yes                   3,737    
  3,328           C        0.054                                       47.286               \>T                    193          T \> M                                            Yes                   3,884    
  3,340           C        0.055                                       4.646                \>T                    197          P \> L                                            Yes                   3,896    
  3,373           T        0.015                                       10.176               \>A                    208          V \> E                                            Yes                   3,929    
  *Nd2*           3,953    T                                           0.029                37.104                 \>C          14                                                F \> L                Yes      4,509
  3,997           A        0.037                                       37.327               DEL A                  28           FrShift                                           Yes                   4,553    
  4,733           A        0.007                                       32.312               \>T                    274          N \> Y                                            Yes                   5,289    
  4,826           T        0.030                                       33.102               \>C                    305          F \> L                                            Yes                   5,382    
  4,922           C        0.059                                       44.905               \>A                    337          L \> M                                            Yes                   5,478    
  *CoI*           5,400    T                                           0.051                41.018                 \>C          25                                                W \> R                Yes      5,976
  5,402           A        0.036                                       5.167                \>G                    25           W \> W                                                                  5,978    
  5,539           T        0.014                                       10.745               \>C                    71           M \> T                                            Yes                   6,115    
  5,630           T        0.153                                       40.322               \>C                    101          S \> S                                                                  6,206    
  5,676           A        0.024                                       46.383               \>C                    117          M \> L                                            Yes                   6,252    
  5,697           A        0.000                                       39.583               \>G                    124          T \> A                                            Yes                   6,273    
  5,706           A        0.023                                       4.922                \>G                    127          T \> A                                            Yes                   6,282    
  5,741           T        0.053                                       41.141               \>C                    138          H \> H                                                                  6,317    
  5,830           T        0.022                                       5.124                \>C                    168          I \> T                                            Yes                   6,406    
  5,932           T        0.044                                       42.419               \>C                    202          L \> P                                            Yes                   6,508    
  6,038           C        0.014                                       30.930               \>T                    237          F \> F                                                                  6,614    
  6,086           T        0.014                                       30.695               \>C                    253          I \> I                                                                  6,662    
  6,149           A        0.034                                       31.097               \>G                    274          V \> V                                                                  6,725    
  6,221           T        0.036                                       31.465               \>C                    298          D \> D                                                                  6,797    
  6,269           T        0.037                                       10.860               \>C                    314          I \> I                                                                  6,845    
  6,311           C        0.107                                       31.338               \>T                    328          H \> H                                                                  6,887    
  6,534           T        0.029                                       4.620                \>C                    403          F \> S                                            Yes                   7,110    
  6,633           A        0.011                                       42.986               \>G                    436          M \> V                                            Yes                   7,209    
  6,666           T        0.011                                       10.908               \>C                    447          Y \> H                                            Yes                   7,242    
  6,765           C        0.026                                       36.510               \>T                    480          R \> W                                            Yes                   7,341    
  6,861           A        0.014                                       35.214               \>T                    512          K \> Stop                                         Yes                   7,437    
  *CoII*          7,079    T                                           0.027                35.953                 \>C          23                                                F \> L                Yes      7,652
  7,136           A        0.055                                       44.564               \>G                    42           I \> V                                            Yes                   7,709    
  7,246           C        0.093                                       43.508               \>G                    78           L \> L                                                                  7,819    
  7,417           G        0.026                                       43.893               \>A                    135          L \> L                                                                  7,990    
  *Atp8*          7,830    T                                           0.040                45.416                 \>C          22                                                I \> T                Yes      8,430
  *Atp6*          7,981    A                                           0.013                33.690                 \>G          19                                                I \> V                Yes      8,581
  8,002           T        0.013                                       44.333               \>C                    26           F \> L                                            Yes                   8,602    
  8,004           T        0.027                                       10.520               \>C                    26           F \> F                                                                  8,604    
  8,017           T        0.041                                       34.119               \>C                    31           F \> L                                            Yes                   8,617    
  8,278           C        0.026                                       10.818               \>T                    118          R \> W                                            Yes                   8,878    
  *Atp6 /CoIII*   8,607    A                                           0.026                9.648                  \>G          227/1                                             Stop \> Stop/M \> M            9,207
  *CoIII*         8,676    G                                           0.065                99.991                 \>A          24                                                A \> T                Yes      9,276
  8,875           A        0.000                                       4.783                \>G                    90           E \> G                                            Yes                   9,475    
  8,945           A        0.000                                       10.046               \>G                    113          G \> G                                                                  9,545    
  8,996           A        0.027                                       9.081                \>C                    130          P \> P                                                                  9,596    
  9,008           T        0.028                                       9.633                \>G                    134          T \> T                                                                  9,608    
  9,106           T        0.013                                       43.745               \>C                    167          I \> T                                            Yes                   9,706    
  9,292           C        0.196                                       45.462               \>T                    229          S \> L                                            Yes                   9,892    
  *Nd3*           9,460    T                                           1.124                0.010                  DEL T        1                                                 FrShift               Yes      10,060
  9,461           T        53.846                                      0.015                \>C                    1            M \> M                                                                  10,061   
  9,632           A        0.024                                       9.456                \>G                    58           V \> V                                                                  10,232   
  9,638           T        0.000                                       9.529                \>C                    60           I \> I                                                                  10,238   
  *Nd4L*          9,977    A                                           0.034                4.721                  \>G          34                                                E \> G                Yes      10,570
  10,022          T        0.116                                       43.147               \>A                    49           L \> Q                                            Yes                   10,615   
  10,060          A        0.000                                       4.839                \>G                    62           T \> A                                            Yes                   10,653   
  10,072          T        0.016                                       10.906               \>C                    66           F \> L                                            Yes                   10,665   
  *Nd4*           10,342   A                                           0.014                42.844                 \>G          59                                                D \> G                Yes      10,935
  10,596          A        0.000                                       10.864               \>G                    144          N \> D                                            Yes                   11,189   
  10,610          T        0.000                                       10.638               \>C                    148          Y \> Y                                                                  11,203   
  10,786          T        0.021                                       4.693                \>C                    207          M \> T                                            Yes                   11,379   
  10,903          T        0.020                                       40.613               \>C                    246          I \> T                                            Yes                   11,496   
  11,227          T        0.030                                       10.145               \>C                    354          L \> P                                            Yes                   11,820   
  11,283          A        0.035                                       31.306               \>G                    373          I \> V                                            Yes                   11,876   
  11,323          T        0.020                                       30.334               \>C                    386          F \> S                                            Yes                   11,916   
  11,489          A        0.014                                       43.339               \>G                    441          M \> M                                                                  12,082   
  11,518          C        0.043                                       33.252               \>A                    451          P \> Q                                            Yes                   12,111   
  *Nd5*           12,000   A                                           0.014                31.510                 \>G          87                                                I \> V                Yes      12,595
  12,160          T        0.037                                       4.849                \>C                    140          L \> P                                            Yes                   12,755   
  12,213          T        0.022                                       10.250               \>C                    158          W \> R                                            Yes                   12,808   
  12,236          T        0.030                                       31.976               \>C                    165          N \> N                                                                  12,831   
  12,414          G        20.418                                      0.039                \>A                    225          A \> T                                            Yes                   13,009   
  12,440          A        0.008                                       9.935                \>G                    233          L \> L                                                                  13,035   
  12,462          A        0.016                                       31.829               \>G                    241          T \> A                                            Yes                   13,057   
  12,510          A        0.008                                       9.750                \>G                    257          I \> V                                            Yes                   13,105   
  12,529          T        0.016                                       33.597               \>C                    263          F \> S                                            Yes                   13,124   
  12,572          A        0.015                                       10.042               \>G                    277          M \> M                                                                  13,167   
  12,597          T        0.022                                       4.870                \>C                    286          L \> L                                                                  13,192   
  12,765          T        0.029                                       41.219               \>A                    342          C \> S                                            Yes                   13,360   
  12,996          A        0.029                                       46.237               \>G                    419          T \> A                                            Yes                   13,591   
  13,052          T        1.586                                       32.567               INS C                  437          FrShift                                           Yes                   13,647   
  13,233          T        0.022                                       45.182               \>C                    498          F \> L                                            Yes                   13,828   
  13,305          T        0.007                                       4.275                \>C                    522          F \> L                                            Yes                   13,900   
  13,398          C        0.069                                       99.940               \>T                    553          L \> L                                                                  13,993   
  13,442          A        0.038                                       42.040               \>G                    567          S \> S                                                                  14,037   
  13,497          T        0.014                                       4.727                \>C                    586          L \> L                                                                  14,092   
  *Nd6*           13,654   A                                           0.024                46.144                 \>T          139                                               I \> M                Yes      14,254
  13,948          T        0.032                                       35.247               \>C                    41           L \> L                                                                  14,551   
  *Cytb*          14,148   A                                           0.021                4.849                  \>G          2                                                 T \> A                Yes      14,750
  14,151          A        0.021                                       42.171               \>G                    3            N \> D                                            Yes                   14,753   
  14,207          A        0.038                                       40.587               \>G                    21           L \> L                                                                  14,809   
  14,345          A        0.036                                       33.216               \>T                    67           T \> T                                                                  14,947   
  14,574          A        0.022                                       31.714               \>G                    144          T \> A                                            Yes                   15,176   
  14,745          C        0.070                                       33.947               \>T                    201          H \> Y                                            Yes                   15,347   
  14,777          A        0.036                                       10.641               \>G                    211          L \> L                                                                  15,379   
  14,797          T        0.022                                       44.566               \>C                    218          I \> T                                            Yes                   15,399   
  14,802          T        0.007                                       5.513                \>C                    220          F \> L                                            Yes                   15,404   
  15,030          T        0.022                                       8.968                \>C                    296          L \> L                                                                  15,632   
  15,145          T        0.008                                       4.545                \>C                    334          I \> T                                            Yes                   15,747   
  15,241          T        0.014                                       9.047                \>C                    366          M \> T                                            Yes                   15,843   

\* Reference sequence.

\*\* "Yes" if the mutation is a non-synonymous mutation.

10.1371/journal.pone.0213283.t003

###### Mutations in rRNA and tRNA, or non-coding regions occurring at a frequency above 1% in cybrid cells.

![](pone.0213283.t003){#pone.0213283.t003g}

  Gene                                             N.P.     Ref[\*](#t003fn001){ref-type="table-fn"}   Mutation frequency   Most frequent change   Human N.P.   
  ------------------------------------------------ -------- ------------------------------------------ -------------------- ---------------------- ------------ --------
  *tRNA-Phe*                                       45       A                                          0.023                11.442                 \>G          623
  *12S rRNA*                                       88       T                                          0.037                40.033                 \>C          667
  177                                              G        0.045                                      45.691               \>A                    754          
  273                                              A        0.030                                      4.530                \>C                    852          
  816                                              A        0.089                                      99.983               \>T                    1,392        
  843                                              A        0.029                                      30.641               \>G                    1,420        
  *tRNA-Val*                                       1,033    A                                          0.015                31.182                 \>G          1,610
  *16S rRNA*                                       1,144    T                                          0.007                10.113                 \>C          1,720
  1,218                                            A        0.007                                      9.562                \>G                    1,790        
  1,328                                            A        0.015                                      4.820                \>G                    1,900        
  1,373                                            A        0.053                                      39.642               \>G                    1,945        
  1,381                                            A        0.044                                      44.471               \>G                    1,952        
  1,551                                            A        0.007                                      38.831               \>G                    2,123        
  1,795                                            A        0.028                                      10.260               \>G                    2,363        
  1,819                                            C        0.074                                      46.556               \>T                    2,386        
  1,935                                            T        0.023                                      9.536                \>C                    2,498        
  2,215                                            G        0.023                                      31.925               \>A                    2,776        
  2,468                                            T        0.069                                      43.184               \>C                    3,026        
  2,555                                            T        0.022                                      4.398                \>C                    3,114        
  2,620                                            T        0.015                                      9.891                \>C                    3,176        
  *tRNA-Ile*                                       3,747    T                                          0.014                40.502                 \>C          4,304
  *tRNA-Gln*                                       3,777    A                                          0.029                41.356                 \>G          4,334
  3,807                                            T        0.023                                      37.029               \>A                    4,364        
  *tRNA-Met*                                       3,852    T                                          0.023                34.223                 \>C          4,409
  3,909                                            T        0.015                                      4.964                \>A                    4,465        
  *tRNA-Trp*                                       4,963    A                                          0.021                33.681                 \>G          5,525
  4,980                                            T        0.063                                      5.725                \>C                    5,543        
  *tRNA-Ala*                                       5,019    A                                          0.034                43.497                 \>G          5,588
  *tRNA-Asn*                                       5,137    A                                          0.016                31.232                 \>T          5,705
  Rep-Ori[\*\*](#t003fn002){ref-type="table-fn"}   5,171    G                                          3.898                64.944                 INS A        5,741
  5,172                                            A        3.161                                      0.867                DEL A                  5,742        
  *tRNA-Ser(UCN)*                                  6,889    A                                          0.015                11.716                 \>G          7,465
  6,926                                            A        0.040                                      44.828               \>G                    7,502        
  *tRNA-Asp*                                       6,950    A                                          0.027                5.414                  \>G          7,526
  *tRNA-Gly*                                       9,399    A                                          0.022                4.793                  \>G          9,999
  *tRNA-His*                                       11,574   T                                          0.034                48.750                 \>C          12,167
  *tRNA-Leu(CUN)*                                  11,696   T                                          0.014                41.697                 \>C          12,291
  D-loop                                           15,588   C                                          99.931               0.020                  \>T          16,290
  15,651                                           T        0.030                                      4.484                \>C                    16,362       
  15,974                                           A        0.024                                      9.471                \>G                    128          
  16,176                                           T        0.022                                      10.159               \>C                    405          

\* Reference sequence.

\*\* Replication origin.

Among mutations located in the protein-coding regions, no homologous mutations that constituted exact matches at base level to human pathogenic mutations were identified. However, three mutations resulted in changes of a homologous amino acid because they affected the same triplet codon as mutations in human. These mutations affected homologous amino acid but their effects (specific amino acid changes) were different from those observed in human disease cases ([S3 Table](#pone.0213283.s005){ref-type="supplementary-material"}). Therefore, although these three mutations were located at sites homologous to those of human pathogenic mutations, their effects on the function or structure of the encoded protein products were probably not homologous to human.

Among mutations in the tRNA-coding regions, three mutations occurred at bases homologous to those observed in human disease cases. Since both sites and base changes (the before and after status) corresponded to human cases, their effects on encoded products might be analogous to those in human diseases.

Next, we explored mutations homologous to confirmed pathogenic mutations in human mtDNA among mutations that occurred in the cybrids at a frequency below 1%. For all the confirmed pathogenic mutations listed in MITOMAP (last accessed: 17 December, 2018), whose pathogenicity has been strongly suggested, we surveyed the mutation rate of homologous mutations in the cybrids ([S4 Table](#pone.0213283.s006){ref-type="supplementary-material"}). As of December 2018, 83 confirmed pathogenic mutations were listed in MITOMAP. The frequency of the most frequently occurring homologous mutations was below 0.1%, indicating that these potential pathogenic mutations were contained at a very low frequency. Considering the *tRNA*^*Leu(UUR)*^ gene, known as a hotspot of human pathogenic mutations, the mutation rate of each base in B82mtB6 and B82mt*PolG*^mut/mut^ cells was similar ([Fig 2F](#pone.0213283.g002){ref-type="fig"}).

In summary, even though B82mt*PolG*^mut/mut^ cells contained various mutations at a higher frequency, not many mutations that occurred at a frequency of at least 1% were homologous to human pathogenic mutations, with respect to both site and quality.

Abnormal respiratory complex formation in B82mt*PolG*^mut/mut^ cells {#sec015}
--------------------------------------------------------------------

Although B82mt*PolG*^mut/mut^ cells harbored few mutations homologous to human pathogenic mutations, they exhibited severe respiration defects. To determine the molecular mechanisms underpinning these respiration defects, we analyzed mitochondrial proteins by clear native PAGE \[[@pone.0213283.ref017]\] ([Fig 3A](#pone.0213283.g003){ref-type="fig"}). The experiment clearly demonstrated that complex I was dramatically reduced and almost undetectable in B82mt*PolG*^mut/mut^ cells. The reduction was more pronounced therein than in B82mtΔ cells, a cybrid with mtDNA with a large-scale deletion (ΔmtDNA) \[[@pone.0213283.ref003]\], which lacking genes encoding multiple subunits of complex I ([Fig 3A](#pone.0213283.g003){ref-type="fig"}). Considering the possibility of formation of a functional complex I in the absence of NDUFA9, the subunit used for the detection of complex I in clear native PAGE, we then evaluated the in-gel activity of complex I ([Fig 3B](#pone.0213283.g003){ref-type="fig"}). The activity of complex I was almost completely undetectable in this assay. On the other hand, complex II, all of which components are encoded by nuclear DNA, was not affected; the amounts of complex III and V were slightly reduced; and the mobility of complex IV exhibited a molecular mass shift to lower masses in B82mt*PolG*^mut/mut^ cells ([Fig 3A](#pone.0213283.g003){ref-type="fig"}).

![Abnormal respiratory complex formation in B82mt*PolG*^mut/mut^ cells.\
(**A**) Detection of the formed respiratory complexes by clear native PAGE. (**B**) In-gel evaluation of the activity of complex I. (**C**) Western blot analysis of the subunits of each respiratory complex (left) and band intensity quantification (right). Left: N and M refer to the nuclear DNA-encoded and mtDNA-encoded subunits, respectively. (**D**) Western blot analysis of mitochondrial chaperons, co-chaperons, and protease (left), and band intensity quantification (right). Data are presented as the mean + S.D. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001, according to an independent two-tailed *t*-test (*n* = 3).](pone.0213283.g003){#pone.0213283.g003}

We next evaluated the relative abundances of the subunits from complexes I and IV (the most affected complexes), and II (the unaffected complex). The data indicated that in addition to the changed abundances of mtDNA-encoded subunits, the abundances of nuclear DNA-encoded subunits of complexes I and IV were substantially altered ([Fig 3C](#pone.0213283.g003){ref-type="fig"}). By contrast, the abundances of complex II subunit were not significantly affected.

Since abnormal complex formation and unbalanced subunit levels were observed, we then examined the expression of representative chaperons and a protease, to determine whether the mitochondrial protein quality control system was experiencing stress. Although the expression of Hsp60 (also known as Hspd1), a major mitochondrial chaperon \[[@pone.0213283.ref019]\], was not significantly altered, the expression of mtHsp70 (also known as Grp75, Mortalin, or Hspa9), a key factor for protein folding in the matrix \[[@pone.0213283.ref020]\] and for protein import from the cytosol to the mitochondrion \[[@pone.0213283.ref021]\], was slightly up-regulated ([Fig 3D](#pone.0213283.g003){ref-type="fig"}). The expression of both, the long and short isoforms of Tid1 (also known as Dnaja3) \[[@pone.0213283.ref022]\], a co-chaperone for mtHsp70 and activator of its ATPase activity \[[@pone.0213283.ref023], [@pone.0213283.ref024]\], was dramatically increased. The expression of mitochondrial serine protease Lonp1 (also known as Prss15) was similarly elevated ([Fig 3D](#pone.0213283.g003){ref-type="fig"}).

Discussion {#sec016}
==========

In the current study, we investigated the possibility of using specific cybrids for mtDNA mutation accumulation, as a starting point for the investigation of links between specific mutations and disease. Deep-sequence analysis of the generated cybrid cells revealed that they harbored various mtDNA mutations at a higher frequency. Although the reported mutation rates in tissues of mutator mice depend on the methods or materials used (tissue type, animal age, and nuclear background used), they range, roughly, from several to dozen bases per 10 kb \[[@pone.0213283.ref007], [@pone.0213283.ref008], [@pone.0213283.ref018], [@pone.0213283.ref025]\]. In addition, we determined the mutation rate in platelets. The rate of 13.97 mutations per 10 kb ([Table 1](#pone.0213283.t001){ref-type="table"} and [Fig 2A](#pone.0213283.g002){ref-type="fig"}) was consistent with previous reports of other tissues. In contrast, the mutation rate in B82mt*PolG*^mut/mut^ cells was 25.07 bases per 10 kb over all mtDNA molecules ([Table 1](#pone.0213283.t001){ref-type="table"}), which is several times higher than that reported in tissues and platelet \[[@pone.0213283.ref007], [@pone.0213283.ref008], [@pone.0213283.ref018], [@pone.0213283.ref025]\]. However, even more striking than the overall average mutation rate, several specific mutations accumulated at a high frequency in the generated cybrid cells. The frequency of occurrence of many mutations was over 40% in B82mt*PolG*^mut/mut^ cells ([Fig 2C](#pone.0213283.g002){ref-type="fig"}). These mutation frequencies were higher than any other rates for tissues of mutator mouse, such as the brain and heart \[[@pone.0213283.ref026]\], skeletal muscle \[[@pone.0213283.ref027]\], liver \[[@pone.0213283.ref028]\], and platelets reported here ([Fig 2D](#pone.0213283.g002){ref-type="fig"}). Mutations that occur at such high rates appear to be either fixed in mice over generations via the germline \[[@pone.0213283.ref018]\], or increase by random segregation \[[@pone.0213283.ref029]\] and/or clonal expansion \[[@pone.0213283.ref030], [@pone.0213283.ref031]\] after introduction into cultured cells.

Furthermore, most mutations occurring at a frequency above 1% in B82mt*PolG*^mut/mut^ cells converged around either approximately 5%, 10%, or 40% ([Fig 2C](#pone.0213283.g002){ref-type="fig"}). If each mutation rate increases or decreases randomly, such convergence would not occur. Thus, it appeared that the converged status was stable, and that some mechanisms might exists that maintain it. We suggest two hypothetical mechanisms. One involves the severity of pathogenesis of each mutation. Upper limits of mutation rates might exist in cells, depending on the mutation pathogenicity, split into roughly three stages. However, approximately 40% of mutations contained both synonymous and non-synonymous mutations, and mutations occurred at sites homologous to those of human pathogenic mutations were also contained. Approximately 5% of mutations also contained all of these mutations similarly. Thus, it cannot be simply assumed that pathogenicity of approximately 40% of mutations was low and that of approximately 5% of mutations was high. According to the other hypothetical mechanism, mutations that converged at similar mutation rates are linked on the same mtDNA molecule, with each mtDNA molecule containing approximately 5%, 10%, or 40% of the total mtDNA pool in B82mt*PolG*^mut/mut^ cells. In support of this hypothesis, it should be assumed that a heavily biased clonal expansion has occurred. In fact, it has been reported that in mutator mouse, tissue cells exhibiting respiration defects accumulate certain non-synonymous mutations at high frequency \[[@pone.0213283.ref016]\]. Further, clonal expansion was also observed after some drug treatments \[[@pone.0213283.ref032]\] or in tumor cells \[[@pone.0213283.ref033]\]. Taking into account these previous reports and the fact that the cybrids are tumor cells derived from fibrosarcoma, the possibility that clonal expansion plays a role in the convergence of mutation rates observed in B82mt*PolG*^mut/mut^ cells is conceivable. We thus developed a hypothesis related to the high mutation frequency following clonal expansion: Because platelets are very small cells, not all mutations we revealed in [S2 Table](#pone.0213283.s004){ref-type="supplementary-material"} would be contained in one or even a small number of platelets that fuse with ρ^0^B82 cells, indicating that a subpopulation of mutant mtDNAs would be introduced into ρ^0^B82 cells through cell fusion. Considering that B82 cells are considerably larger than platelets, the small number of mtDNAs introduced would replicate and increase in number. It can be considered that this process is similar to that of mtDNA bottlenecking during oocyte development. Previously, it was proposed that biased replication of a subpopulation of mtDNAs results in the genetic bottleneck of mtDNA \[[@pone.0213283.ref034]\]. This biased replication could occur in the generated cybrid cells and induces the clonal expansion of some specific mtDNA molecules without any selection, as ρ^0^B82 cells can harbor severe pathogenicities induced by predominant accumulation of pathogenic mtDNAs, owing to their respiration defect resistance ([S2 Fig](#pone.0213283.s002){ref-type="supplementary-material"}). In animal tissues or organs, no mtDNA-less cells are present except for terminally differentiated erythrocytes, and mitochondrial respiration-null cells would not survive. In contrast, ρ^0^B82 cells can survive without mtDNA and adapt to and/or resist a mitochondrial respiration-free environment. We consider that this strong resistance to respiration defects and biased replication of mtDNA enable pathogenic mtDNA mutations to accumulate at a high frequency. The higher frequency but lower diversity of mtDNA mutations in our cybrid cells compared with parental platelets ([Fig 2A--2E](#pone.0213283.g002){ref-type="fig"}) also supports our hypothesis related to biased replication of a subpopulation of mtDNA in parental platelets ([S2 Fig](#pone.0213283.s002){ref-type="supplementary-material"}).

At the same time, notably, whereas B82mt*PolG*^mut/mut^ cells harbored various mutations, including non-synonymous mutations, at a high frequency, almost no mutations homologous to human pathogenic mutations were observed ([S3 Table](#pone.0213283.s005){ref-type="supplementary-material"}). When the entire mtDNA molecules were compared, it was apparent that the mtDNA mutation rate in B82mt*PolG*^mut/mut^ cells was significantly higher than that in B82mtB6 cells ([Table 1](#pone.0213283.t001){ref-type="table"} and [Fig 2A and 2B](#pone.0213283.g002){ref-type="fig"}). However, when the comparison region was restricted to the *tRNA*^*Leu(UUR)*^ gene, the hotspot of human pathogenic mtDNA mutations, the mutation rates for each base in B82mtB6 and B82mt*PolG*^mut/mut^ cells were not significantly different ([Fig 2E](#pone.0213283.g002){ref-type="fig"}), indicating that the frequency of mutations in this region was not increased by *PolG* mutation. Focusing on a more specific site, the A2689G mutation, a mutation homologous to human A3243G mutation, which is the most frequent mutation observed in human mitochondrial diseases, no such reads were detected among 13,997 reads in B82mtB6. Even in the B82mt*PolG*^mut/mut^ cells, only two such reads were identified among 19,201 reads ([S1 Table](#pone.0213283.s003){ref-type="supplementary-material"}). These observations suggested that mutation hotspot regions in human mtDNA and hotspot regions induced by *PolG*^mut/mut^ in mouse mtDNA are dissimilar.

Although we did not identify mutations homologous to confirmed human pathogenic mutations that occurred at a high frequency in B82mt*PolG*^mut/mut^ cells, these cells exhibited severe respiration defects ([Fig 1B and 1C](#pone.0213283.g001){ref-type="fig"}). Abnormal respiratory complex formation appeared to be involved in these respiration defects. In the most affected complex I, whereas drastic changes in the expression of complex subunits were observed, not all of them were completely lost ([Fig 3C](#pone.0213283.g003){ref-type="fig"}). However, the formation and function of complex I were almost entirely abolished ([Fig 3A and 3B](#pone.0213283.g003){ref-type="fig"}). Although abnormal respiratory complex formation has been reported in mutator mouse tissues \[[@pone.0213283.ref035]\], almost complete disappearance of complex I observed in the cybrid cells in the current study was much more severe than that observed in mouse tissues. These exceedingly severe abnormalities were not lethal to the cultured cell line, in contrast with mouse tissues or organs. Furthermore, the increased expression of chaperons, co-chaperons, and a protease in the B82mt*PolG*^mut/mut^ cells ([Fig 3D](#pone.0213283.g003){ref-type="fig"}) probably reflected accelerated protein degradation by proteases because of the shortened lifespan of respiratory complexes incorporating abnormal subunits, and activated protein transport from the cytosol to the mitochondrial matrix to recruit subunits to replace the ones that had been degraded.

Analyses presented in the current study revealed that a cultured cell line can indeed harbor various mtDNA mutations that occur at a high frequency, and can be maintained regardless of the induced severe respiration defects, which are not viable in mouse tissues. On the other hand, despite the fact that the generated cybrids harbored various mutations, few mutations homologous to human pathogenic mutations were identified. Therefore, it might be challenging to use the generated cybrids as a source of mutations for the development of novel mouse models of specific human diseases. However, cultured cells that harbor frequently occurring harmful mutations are very useful tools for concentrating mtDNA mutations. Some of the mutations identified in the current study might be pathogenic mutations that are common predisposing factors for human diseases, even if the mutation sites are not entirely consistent with human. Importantly, since ρ^0^B82 cells, the mtDNA recipient cells used in this study, express wildtype *PolG*, accumulation of *de novo* mtDNA mutations rarely occurred in re-populated mtDNA molecules after fusion. Our sequence analysis suggested that at least a portion of re-populated mtDNAs were clonally expanded from the small population of introduced mtDNAs ([S2 Fig](#pone.0213283.s002){ref-type="supplementary-material"}). Many mutations were linked on the same mtDNA molecule, and as a result, the effects of individual mutations in this condition in our current cybrid cells cannot be evaluated; however, controlling the mutation load in parental platelets by generation, age, or mtDNA refresh through mating of male mutator mice with female wild-type mice \[[@pone.0213283.ref018]\], may enable control of mtDNA populations in established cybrid cells. When the small population of introduced mtDNAs harbor useful mutations, the mutations can be concentrated in generated cybrid at levels that would be fatal in mouse tissue. Ultimately, these mutations can be introduced into mouse at appropriate mutation rate \[[@pone.0213283.ref036]\], and novel mouse models of mtDNA-based diseases can be generated. The generated mouse models may facilitate understanding of the mechanism of diverse disease phenotypes due to mtDNA mutations.

Supporting information {#sec017}
======================

###### Scheme for the establishment of transmitochondrial cybrids.

For the experiment, ρ^0^B82 cells and platelets obtained from mice were used as mtDNA recipients and donors, respectively. Recipient and donor cells were fused using the polyethylene glycol method, and the resultant transmitochondrial cybrids were selected by culturing in a selective medium (see [Materials and Methods](#sec002){ref-type="sec"} for details).
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Click here for additional data file.

###### Schematic illustration of the predicted process by which mtDNA mutations are concentrated at high frequency.

The platelets contain diverse mtDNA mutations as a population, but "real parental" platelets, which fuse with ρ^0^B82 cells, harbor only a portion thereof. Because ρ^0^B82 cells are larger than platelets, the introduced mtDNA molecules replicate and increase in number after cell fusion. Because of the biased replication of mtDNA, a subpopulation of mtDNA molecules dominantly increases, and mutations on those molecules also increase simultaneously. Although accumulation of various mtDNA mutations at high frequency induces severe respiration defects, the generated cybrid cells can survive and proliferate because of their resistance to the mitochondrial respiration-null condition, which was acquired during the ρ^0^ state. As a result, a subpopulation of mutations in the parental platelets is concentrated, resulting in a higher mutation frequency, but the diversity of mutations is lower than that of parental platelets.
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Click here for additional data file.

###### Mutation analysis of cybrid cells.
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###### Mutation analysis of platelets.
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###### Mutations homologous to human pathogenic mutations occurring at a frequency above 1% in B82mt*PolG*^*mut/mut*^ cybrid cells.
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Click here for additional data file.

###### Mutations homologous to human pathogenic mutations occurring at a frequency under 1% in B82mt*PolG*^*mut/mut*^ cybrid cells.

(XLSX)

###### 

Click here for additional data file.
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